CA3048853A1 — Pyrimidine derivative
Assigned to Daiichi Sankyo Co Ltd · Expires 2018-07-05 · 8y expired
What this patent protects
The present invention addresses the problem of providing a compound that, when used in the treatment of cystic fibrosis, which is caused by a mutation of a cystic fibrosis transmembrane conductance regulator (CFTR), which is a kind of chloride channel, opens a chloride channel di…
USPTO Abstract
The present invention addresses the problem of providing a compound that, when used in the treatment of cystic fibrosis, which is caused by a mutation of a cystic fibrosis transmembrane conductance regulator (CFTR), which is a kind of chloride channel, opens a chloride channel differing from the CFTR causative of the disease, and that is effective for the treatment of cystic fibrosis independently of the CFTR. The compound of the present invention is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof. The compound opens a calcium-activated chloride channel (CaCC) by means of G-protein-coupled receptor 39 (GPR39) agonistic activity and has intense chloride-ion-secreting activity.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.